Keck Medicine of USC is enrolling individuals in a phase 3 clinical trial to test monoclonal antibody treatment for COVID-19
Analysis update by the nonprofit Cancer Research Institute reveals dramatic growth in PD-1/PD-L1 monoclonal antibody combination cancer treatment strategies in global clinical trial pipeline
Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
A Phase III clinical trial to assess if a potential vaccine is effective at preventing symptomatic COVID-19 is now open for enrollment by The University of Texas Health Science Center at Houston (UTHealth) in collaboration with Memorial Hermann-Texas Medical Center.
The University of Chicago Medical Center will be a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical research study, ENSEMBLE trial, to evaluate the safety and efficacy of the Janssen’s investigational COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S.
Keck Medicine of USC enrolling individuals in phase 3 clinical trial to treat mild Alzheimer’s disease using deep brain stimulation.
Researchers at the University of Chicago Medicine are launching a four-year research trial to test the effects of two evidenced-based interventions for personalized diabetes care for older adults, thanks to a new $5 million grant provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health.
The NCCN Oncology Research Program (ORP) plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2), supported by a $2-million grant from Puma Biotechnology, Inc.
AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center (VUMC) and optimized by AstraZeneca.
In a new COVID-19 clinical trial, Stuart Cohen at UC Davis Health evaluates the efficacy, safety and tolerability of monoclonal antibody combination in adults exposed to patients with COVID-19. It is the same antibody drug given to President Trump to treat his COVID-19.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right